MID-VOLUME · HOSP-HEAVY
rifaximin Side Effects
rifaximin (also sold as Xifaxan) sits MID-VOLUME #238 of 524 by FAERS report count. Lead signal: HOSP-HEAVY - 39.1% mention hospitalization (7,784 reports). Demographics and serious-outcome tables follow.
Data updated 2026-05-15
- 19,891
- FAERS reports
FDA Adverse Event Reporting System extract for rifaximin. Stamp set WATCHLIST · DEATH-HEAVY · HOSP-HEAVY. How figures are compiled.
rifaximin: 39.1% mention hospitalization (7,784 reports). Death stamp DEATH-HEAVY; volume band MID-VOLUME #238 of 524 by FAERS report count.
Mid-book FAERS page for rifaximin (Xifaxan) (19,891 reports). Signature HOSP-HEAVY. Dominant age band on file: 45-64. Educational reference only.
Counts from the openFDA FAERS extract (2004–2025). Stamps WATCHLIST · DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED.
DEATH leads 3,982 of 19,891 reports
Who reports · age peak 45-64 (SEX-BALANCED)
Sex coding · SEX-BALANCED
Age peak 45-64 (5,220 reports)
FAERS filings rising toward 2025
Reactions in Death Reports
Death-mentioned subset is HEAVY here (5,855 reports, 29.4%). Top co-reported reactions in that subset - voluntary, not causal.
| Reaction | Reports |
|---|---|
| DEATH | 3,977 |
| HEPATIC CIRRHOSIS | 378 |
| HEPATIC FAILURE | 329 |
| RENAL FAILURE | 251 |
| HOSPITALISATION | 208 |
| LIVER DISORDER | 176 |
| THERAPY INTERRUPTED | 170 |
| HEPATIC ENCEPHALOPATHY | 161 |
| HOSPICE CARE | 160 |
| PNEUMONIA | 144 |
| SEPSIS | 124 |
| FALL | 118 |
| AMMONIA INCREASED | 115 |
| HEPATIC CANCER | 112 |
| DIARRHOEA | 98 |
| INSURANCE ISSUE | 94 |
| MULTIPLE ORGAN DYSFUNCTION SYNDROME | 92 |
| CONDITION AGGRAVATED | 90 |
Reactions in Hospitalization Reports
Hospitalization is HEAVY (7,784, 39.1% of the book). Top reactions in those rows:
| Reaction | Reports |
|---|---|
| HOSPITALISATION | 1,697 |
| AMMONIA INCREASED | 696 |
| THERAPY INTERRUPTED | 628 |
| HEPATIC ENCEPHALOPATHY | 618 |
| CONFUSIONAL STATE | 473 |
| FALL | 445 |
| INABILITY TO AFFORD MEDICATION | 399 |
| DIARRHOEA | 398 |
| DEATH | 390 |
| INSURANCE ISSUE | 358 |
| PNEUMONIA | 343 |
| HEPATIC CIRRHOSIS | 335 |
| CONDITION AGGRAVATED | 316 |
| NAUSEA | 297 |
| DYSPNOEA | 284 |
| FATIGUE | 273 |
| LIVER DISORDER | 264 |
| ASCITES | 263 |
| HEPATIC FAILURE | 259 |
How to read rifaximin FAERS figures (WATCHLIST · DEATH-HEAVY · HOSP-HEAVY)
FAERS holds 19,891 voluntary reports linked to rifaximin (Xifaxan), 2004-2025. Death is listed on 5,855 (29.4%). Hospitalization appears on 7,784 (39.1%). Top co-reported indication: Product Used For Unknown Indication.
Mid-volume extract - treat DEATH-HEAVY · HOSP-HEAVY as signal-detection rates next to 39.1% mention hospitalization (7,784 reports).
Read with rifaximin
Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-HEAVY · HOSP-HEAVY stamps.
ABS(total_reports) peer at 19,947 FAERS cases (Δ 56 heavier vs rifaximin); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's WATCHLIST · DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED.
ABS(total_reports) peer at 19,831 FAERS cases (Δ 60 lighter vs rifaximin); DEATH-MARKED · HOSP-MID · SEX-BALANCED vs this page's WATCHLIST · DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED.
ABS(total_reports) peer at 19,772 FAERS cases (Δ 119 lighter vs rifaximin); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's WATCHLIST · DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED.
ABS(total_reports) peer at 20,197 FAERS cases (Δ 306 heavier vs rifaximin); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's WATCHLIST · DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED.
ABS(death_share) pole at 62.1% death-mentioned reports (Δ 32.7 pp vs rifaximin's DEATH-HEAVY): CASELOAD · HOSP-MID.
rifaximin stamps DEATH-HEAVY · HOSP-HEAVY; FAERS outcome shares are signal-detection rates, not incidence. Read them next to caseload WATCHLIST and the label guide.